SecSonar.com

Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Enanta Pharmaceuticals, Inc. (ENTA) is a Biotechnology company based in US with a market capitalization of $305.7M. Revenue declined 3.4% year-over-year and free cash flow was negative at -$32.2M. This page tracks ENTA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 131 employees · IPO Mar 21, 2013

Valuation

Valuation & price

$13.41 · as of May 17, 2026 · -20.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.72

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$16.60$11.55$6.49Jul 25Dec 25Jul 26Jul 7, 25$7.65Jul 9, 25$7.13Jul 11, 25$6.56Jul 15, 25$6.59Jul 17, 25$7.23Jul 21, 25$7.73Jul 23, 25$7.73Jul 25, 25$7.40Jul 29, 25$8.10Jul 31, 25$7.58Aug 4, 25$7.10Aug 6, 25$7.12Aug 11, 25$6.49Aug 13, 25$7.58Aug 15, 25$8.00Aug 19, 25$8.39Aug 21, 25$8.59Aug 25, 25$8.66Aug 27, 25$8.53Aug 29, 25$8.40Sep 3, 25$8.82Sep 5, 25$8.85Sep 9, 25$9.04Sep 11, 25$8.66Sep 16, 25$7.45Sep 18, 25$7.84Sep 22, 25$7.70Sep 24, 25$7.81Sep 26, 25$7.90Sep 30, 25$11.97Oct 2, 25$10.33Oct 6, 25$11.35Oct 8, 25$11.30Oct 10, 25$11.02Oct 14, 25$10.96Oct 16, 25$11.38Oct 21, 25$11.01Oct 23, 25$10.67Oct 27, 25$10.50Oct 29, 25$10.63Oct 31, 25$10.96Nov 4, 25$10.81Nov 6, 25$10.80Nov 10, 25$11.51Nov 12, 25$11.93Nov 14, 25$12.06Nov 18, 25$12.36Nov 20, 25$12.13Nov 25, 25$13.66Nov 28, 25$14.12Dec 2, 25$13.96Dec 4, 25$14.09Dec 8, 25$14.18Dec 10, 25$14.37Dec 12, 25$14.73Dec 16, 25$14.85Dec 18, 25$14.53Dec 22, 25$16.21Dec 24, 25$16.60Dec 29, 25$16.43Jan 2, 26$14.42Jan 6, 26$13.58Jan 8, 26$13.44Jan 12, 26$12.91Jan 14, 26$13.84Jan 16, 26$12.61Jan 21, 26$12.57Jan 23, 26$13.02Jan 27, 26$12.98Jan 29, 26$12.90Feb 2, 26$13.19Feb 4, 26$13.48Feb 9, 26$13.83Feb 11, 26$14.25Feb 13, 26$13.85Feb 18, 26$13.89Feb 20, 26$13.51Feb 24, 26$14.75Feb 26, 26$14.41Mar 2, 26$14.51Mar 4, 26$15.41Mar 6, 26$13.54Mar 10, 26$13.95Mar 12, 26$13.41Mar 17, 26$13.27Mar 19, 26$13.00Mar 23, 26$12.65Mar 25, 26$12.17Mar 27, 26$12.18Mar 31, 26$12.63Apr 2, 26$13.14Apr 7, 26$13.43Apr 9, 26$13.95Apr 13, 26$14.27Apr 15, 26$14.55Apr 17, 26$14.01Apr 22, 26$13.79Apr 24, 26$13.31Apr 28, 26$13.71Apr 30, 26$13.89May 4, 26$14.54May 6, 26$15.24May 8, 26$15.34May 12, 26$14.53May 14, 26$13.81May 18, 26$13.45May 20, 26$13.61May 22, 26$13.95May 28, 26$13.23Jun 1, 26$12.67Jun 3, 26$11.24Jun 5, 26$11.28Jun 9, 26$11.35Jun 11, 26$11.51Jun 15, 26$11.44Jun 17, 26$12.64Jun 22, 26$13.37Jun 24, 26$13.72Jun 26, 26$14.00Jul 2, 26$15.11
$6.4952-week range$16.85
Loading valuation history…

Fundamentals

Key fundamentals

$305.7M

Market cap

-3.4%

Revenue growth (YoY)

93.0%

Gross margin

-$32.2M

Free cash flow (USD)

$12.2M

Net debt

0.8%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$88.3MFY 2017$102.8MFY 2018$206.6MFY 2019$205.2MFY 2020$122.5MFY 2021$97.1MFY 2022$86.2MFY 2023$79.2MFY 2024$67.6MFY 2025$65.3M
$88.3M$65.3M

Free cash flow by year

2016 → 2025

FY 2016$31.1MFY 2017$50.1MFY 2018$26.2MFY 2019$66.0MFY 2020$5.6MFY 2021$-70.7MFY 2022$-86.9MFY 2023$-112.2MFY 2024$-96.7MFY 2025$-32.2M
$31.1M-$32.2M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202593.0%
100.0%93.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCommon Stock Sale AgreementJul 2, 2026Filing
  • 8-K eventPatent InvalidationJun 23, 2026Filing
  • 8-K eventZelicapavir UpdateJun 18, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing

Questions

Frequently asked questions

What is Enanta Pharmaceuticals, Inc.'s market cap?

Enanta Pharmaceuticals, Inc. (ENTA) has a market capitalization of $305.7M.

What is ENTA's P/E ratio?

A meaningful P/E ratio is not available for ENTA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ENTA's price-to-book (P/B) ratio?

ENTA trades at 4.72 times book value per share.

Are insiders buying ENTA stock?

SEC Form 4 filings show no open-market insider buys at Enanta Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

XOMAP

XOMA Corporation

$307M

VSTM

Verastem, Inc.

$303.9M

AMRN

Amarin Corporation plc

$302.3M

ARMP

Armata Pharmaceuticals, Inc.

$300.3M

NAGE

Niagen Bioscience Inc

$311.8M

FATE

Fate Therapeutics, Inc.

$317M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.